Skip to main content
. 2019 Dec 17;11:1759720X19895492. doi: 10.1177/1759720X19895492

Figure 4.

Figure 4.

Odds ratio of venous thromboembolism events in patients with IMIDs treated with tofacitinib compared to placebo.